Promising Targets for Bladder Cancer
Joshua J. Meeks, MD, discusses investigational targets in the bladder cancer space.
Joshua J. Meeks, MD, Edward M. Schaeffer, MD, PhD Professor of Urology, and associate professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, discusses investigational targets in the bladder cancer space.
One of the most promising targeted in bladder cancer to date is FGFR3, according to Meek. In patients with advanced disease or muscle invasive disease, FGFR3 alterations exists but are less frequent compared with early-stage disease. Meeks said the 40% or more patients with early-stage bladder cancer have FGFR3 alterations.
The unanswered questions physicians have is how to target FGFR3, weigh the benefits, and limit treatment toxicity, explained Meeks.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
